Non-alcoholic fatty liver disease (NAFLD) has emerged as the most prevalent liver disease
in the world, yet there are still no approved pharmacological therapies to prevent or treat this …

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …

Our understanding of nonalcoholic fatty liver disease pathophysiology continues to advance
rapidly. Accordingly, the field has moved from describing the clinical phenotype through the …

Peroxisome proliferator-activated receptor (PPAR) α, β/δ, and γ modulate lipid homeostasis.
PPARα regulates lipid metabolism in the liver, the organ that largely controls whole-body …

The increasing epidemic of obesity worldwide is linked to serious health effects, including
increased prevalence of type 2 diabetes mellitus, cardiovascular disease and nonalcoholic …

The progression of chronic liver diseases (CLD), irrespective of etiology, involves chronic
parenchymal injury, persistent activation of inflammatory response as well as sustained …

Nonalcoholic fatty liver disease (NAFLD) and its inflammatory and often progressive subtype
nonalcoholic steatohepatitis (NASH) are becoming the leading cause of liver-related …

Cell-cell communication via ligand-receptor signaling is a fundamental feature of complex
organs. Despite this, the global landscape of intercellular signaling in mammalian liver has …

Peroxisome proliferator–activated receptor α (PPAR α) is a nuclear receptor of clinical
interest as a drug target in various metabolic disorders. PPAR α also exhibits marked anti …

Hepatic fibrosis is a dynamic process characterized by the net accumulation of extracellular
matrix resulting from chronic liver injury of any aetiology, including viral infection, alcoholic …